Background: In the double-blind placebo-controlled randomized Phase III MERiDiAN trial (ClinicalTrials.gov NCT01663727), adding bevacizumab to paclitaxel for HER2-negative metastatic breast cancer (mBC) significantly improved progression-free survival (PFS; stratified hazard ratio [HR] 0.68, 99% confidence interval [CI], 0.51-0.91). We assessed the efficacy and tolerability of first-line bevacizumab-paclitaxel in the subset of Japanese patients in MERiDiAN. Methods: Eligible patients had HER2-negative mBC previously untreated with chemotherapy. Plasma vascular endothelial growth factor (VEGF)-A was measured before randomization to paclitaxel 90 mg/m 2 on Days 1, 8 and 15 with either placebo or bevacizumab 10 mg/kg on Days 1 and 15,
Introduction
In Japan, the monoclonal antibody bevacizumab is an established treatment option for metastatic breast cancer (mBC), given as either first-line or second-line therapy in combination with chemotherapy. Evidence supporting the use of bevacizumab in the first-line setting comes from four randomized Phase III trials: first, the open-label E2100 trial evaluating paclitaxel with or without bevacizumab (1); second, the double-blind placebo-controlled AVADO trial evaluating docetaxel with either bevacizumab or placebo (2) ; third, the two-cohort double-blind placebo-controlled RIBBON-1 trial, comparing capecitabine with either bevacizumab or placebo in one cohort, and taxane or anthracycline-based combination therapy with either bevacizumab or placebo in the other cohort (3); and finally, the recent double-blind placebo-controlled MERiDiAN trial comparing paclitaxel plus placebo versus paclitaxel plus bevacizumab (4) . This fourth trial prospectively evaluated the potential role of baseline plasma vascular endothelial growth factor (VEGF)-A concentration in predicting progression-free survival (PFS) benefit from bevacizumab. All four trials demonstrated significantly improved PFS with the addition of bevacizumab to first-line chemotherapy (1) (2) (3) (4) .
To explore the efficacy of bevacizumab and paclitaxel combination therapy as first-line treatment for HER2-negative mBC specifically in Japanese patients, we conducted an exploratory subgroup analysis of the MERiDiAN trial. Our aim was to assess consistency between the intent-to-treat (ITT) population and the subgroup of Japanese patients treated in the MERiDiAN trial.
Patients and methods

Study design
The design of the double-blind placebo-controlled randomized Phase III MERiDiAN trial (ClinicalTrials.gov, NCT01663727) has been described in detail elsewhere (4) . The trial was conducted in 132 centers in North and South America, Europe, Asia (including Japan) and South Africa. Ethics approval was obtained from each participating institution's Institutional Review Board or Ethics Committee. The present manuscript focuses on the population of patients treated in Japanese centers.
Patients
Eligible patients were aged ≥18 years and had HER2-negative locally recurrent or mBC (LR/mBC) and Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. The main exclusion criteria were: prior chemotherapy for LR/mBC; prior hormonal therapy <2 weeks before randomization; prior (neo)adjuvant chemotherapy <12 months before randomization; prior VEGF pathway-targeted therapy; New York Heart Association Class ≥2 congestive heart failure; left ventricular ejection fraction <55%; history of myocardial infarction, stroke or transient ischemic attack within 6 months before randomization; persistent grade ≥3 sensory neuropathy; baseline neutrophil count <1500 per mm 3 or known CNS disease. Exclusion criteria relating specifically to bevacizumab included: inadequately controlled hypertension; significant vascular disease; serious non-healing wound, active ulcer or untreated bone fracture; proteinuria at screening; previous hypertensive crisis or hypertensive encephalopathy; history of abdominal fistula or gastrointestinal perforation within 6 months before randomization; history of bleeding diathesis or significant coagulopathy (without therapeutic anticoagulation); major surgical procedure within 28 days before randomization or anticipated need for major surgery during the study. All patients provided written informed consent. An important objective of the MERiDiAN trial was prospective evaluation of plasma VEGF-A as a potential predictive marker for PFS benefit from bevacizumab. Mandatory blood samples were collected at screening to determine baseline plasma VEGF-A concentrations for classification into high and low baseline VEGF-A subgroups for stratification. Patients with a baseline plasma VEGF-A level ≥5.05 pg/ml were classified as VEGF-A high ; those with plasma VEGF-A <5.05 pg/ml were classified as VEGF-A low . The cutoff of 5.05 pg/ml represents the median plasma VEGF-A concentration in retrospective biomarker analyses of the AVADO trial (2) . Additional stratification factors were: prior adjuvant chemotherapy (yes versus no); hormone (estrogen and progesterone) receptor status (either or both positive versus both negative) and geographic region (Asia versus North America/Europe versus other).
Treatment
Patients were randomly assigned (1:1) to receive paclitaxel 90 mg/m 2 on Days 1, 8 and 15 combined with either placebo or bevacizumab 10 mg/kg on Days 1 and 15, all given intravenously and repeated every 4 weeks until disease progression, unacceptable toxicity or withdrawal of consent. If one drug was discontinued because of toxicity or any reason other than disease progression, the remaining agent could be continued as monotherapy until disease progression, unacceptable toxicity or withdrawal of consent. Tumors were assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (version 1.1) every 8 weeks until disease progression, regardless of whether the patient was receiving study treatment. Adverse events were recorded at every cycle, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.
Statistical design
The co-primary endpoints in the MERiDiAN trial were investigatorassessed PFS in the ITT population and in the plasma VEGF-A high subgroup. PFS was defined as the interval between randomization and the first record of disease progression or death, whichever occurred earlier. As the MERiDiAN trial was designed to determine whether VEGF-A was a predictive biomarker for bevacizumab treatment effect on PFS, an interaction test was included as a secondary endpoint. Additional secondary endpoints included objective response rate in patients with measurable disease at baseline, duration of objective response in responding patients, overall survival (OS) and safety. Efficacy was analyzed in all randomized patients. Safety was analyzed in all patients who received at least one dose of study medication.
The present analyses of the subgroup of patients treated in Japanese centers are exploratory. Consequently, P values are not reported for comparisons between treatment arms. The randomization stratification factor 'geographic region' was not applied in stratified analyses of efficacy.
Results
Patient population
Of the 481 patients randomized in the MERiDiAN trial, 54 were enrolled at Japanese centers and included in the present subgroup analyses. Baseline characteristics were reasonably balanced between treatment arms in this subgroup ( Table 1 ), except that the bevacizumab-paclitaxel subgroup had a lower median age and included a smaller proportion of patients with triple-negative disease and a smaller proportion previously treated with a taxane-containing regimen. In addition, median plasma VEGF-A concentration was lower in the bevacizumab-paclitaxel subgroup and only 25% of patients were classified as VEGF-A high (compared with 47% in the placebopaclitaxel subgroup).
Compared with the ITT population of MERiDiAN, the Japanese subgroup included a higher proportion of patients with ECOG performance status 0 (87% [both arms pooled] versus 55%, respectively) and a higher proportion of patients with measurable disease (96% versus 86%) (Supplementary Table 1 ). Median plasma VEGF-A level was 4.04 pg/ml in the Japanese population (both treatment arms pooled), which was lower than in the pooled ITT population (5.27 pg/ml).
Treatment exposure
One patient randomized to placebo-paclitaxel and one randomized to bevacizumab-paclitaxel did not receive study treatment; thus the safety population included 52 of the 54 randomized patients. Treatment exposure in the safety population is summarized in Table 2 . Both the mean number of paclitaxel cycles and the proportion of patients continuing paclitaxel for ≥1 year were higher in the bevacizumab-paclitaxel than the placebo-paclitaxel treatment arm, but the mean paclitaxel dose intensity was lower. In the placebopaclitaxel treatment arm, two-thirds of patients discontinued placebo and/or paclitaxel because of disease progression, whereas in the bevacizumab-paclitaxel arm, only 21% discontinued bevacizumab and/or paclitaxel because of disease progression but discontinuations because of adverse events were more common (33% of patients) ( Table 3) .
Efficacy
At the time of data cutoff for the primary PFS analysis (30 November 2014), PFS events had been recorded in 22 of 30 patients (73%) randomized to placebo-paclitaxel and 14 of 24 patients (58%) randomized to bevacizumab-paclitaxel. Median PFS was 9.2 months (95% confidence interval [CI], 5.6-10.9 months) versus 12.7 months (95% CI, 10.9 months-not evaluable), respectively (Fig. 1) . The stratified hazard ratio (HR) for PFS was 0.64 (95% CI, 0.29-1.40), representing a 36% reduction in the risk of progression or death with the addition of bevacizumab to paclitaxel. In the subgroup of 20 patients with high baseline VEGF-A, the HR for PFS was 0.35 (95% CI, 0.08-1.59). Median PFS in the VEGF-A high subgroup was 9.0 months in the 14 patients treated with placebopaclitaxel versus 10.9 months in the 6 patients treated with bevacizumab-paclitaxel (Supplementary Table 2 ).
In the overall Japanese population, median PFS according to Independent Review Facility (IRF) assessment (a prespecified sensitivity analysis in the MERiDiAN trial) in the placebo-paclitaxel arm was consistent with the investigator-assessed PFS results (9.2 months; 95% CI, 5.4-16.7 months). In the bevacizumab-paclitaxel group, PFS events according to IRF assessment were recorded in only nine patients (38%); median PFS was 20.1 months (95% CI, 14.4-not evaluable). The stratified HR was 0.45 (95% CI, 0.18-1.12).
The overall response rate was 46% (95% CI, 28-65%) in the placebo-paclitaxel arm versus 58% (95% CI, 39-78%) in the bevacizumab-paclitaxel arm ( Table 4 ). The median duration of response was 7.4 months (95% CI, 7.2-14.8 months) in the 13 responding patients in the placebo-paclitaxel arm versus 11.0 months (95% CI, 7.8 months-not evaluable) in the 14 responding patients in the bevacizumab-paclitaxel arm. The proportion of patients achieving disease stabilization for ≥24 weeks was 25% in both arms, resulting in clinical benefit rates of 71% in the placebo-paclitaxel arm versus 83% in the bevacizumab-paclitaxel arm. At the updated interim OS analysis (data cutoff 31 July 2015) after OS events in 23 patients (43%), median OS was 25.1 months (95% CI, 19.3 months-not evaluable) in the placebo-paclitaxel arm and had not been reached in the bevacizumab-paclitaxel arm. The OS HR was 0.67 (95% CI, 0.25-1.81).
Safety
All patients in the safety population experienced at least one adverse event (of any grade). The most common adverse events were alopecia (90% in the placebo-paclitaxel arm versus 96% in the bevacizumabpaclitaxel arm) and peripheral sensory neuropathy (76% versus 83%, respectively) (Fig. 2) . Compared with placebo-paclitaxel, bevacizumab-containing therapy was associated with higher incidences (all grades) of peripheral edema, dysgeusia, diarrhea, epistaxis, nail discoloration, constipation, pyrexia, rash, proteinuria, hypertension and face edema. However, in most cases, these events were of Grade 1 or 2 intensity. Grade ≥3 adverse events were more common in the bevacizumab-paclitaxel arm (87%) than in the placebo-paclitaxel arm (48%). The most common Grade ≥3 adverse events were hematologic events (decreased white blood cell count, 21%; decreased neutrophil count, 17%) in the placebo-paclitaxel arm and hematologic events (decreased white blood cell count, 30%; neutropenia, 30%; decreased neutrophil count, 22%) and peripheral sensory neuropathy (17%) in the bevacizumab-paclitaxel arm (Fig. 3) . Grade ≥3 neutropenia, peripheral sensory neuropathy and hypertension were markedly more common with bevacizumab-paclitaxel than placebopaclitaxel. There were two fatal adverse events: one patient (3%) in the placebo-paclitaxel arm died from dyspnea and one patient (4%) in the bevacizumab-paclitaxel arm died from hepatic failure.
Adverse events of special interest for bevacizumab are summarized in Table 5 . Bevacizumab was associated with higher incidences of neutropenia, bleeding, hypertension and proteinuria compared with placebo-paclitaxel, but Grade ≥3 adverse events of special interest were infrequent, except for neutropenia in both treatment arms.
In the placebo-paclitaxel arm, one patient (3%) discontinued both placebo and paclitaxel because of an adverse event (pulmonary edema). In the bevacizumab-paclitaxel arm, nine patients (39%) discontinued either one or both agents because of adverse events (eight [35%] discontinued bevacizumab; eight [35%] discontinued paclitaxel). These comprised four patients who discontinued both bevacizumab and paclitaxel because of adverse events (one case each of frequent bowel movements, asthenia, macular edema and osteomyelitis accompanied by peripheral sensory neuropathy); one patient who discontinued bevacizumab (because of anemia and fatigue) and subsequently paclitaxel (because of hepatic failure); one patient who discontinued paclitaxel (because of osteonecrosis of the jaw and anemia) and subsequently bevacizumab (because of duodenal ulcer); one patient who discontinued paclitaxel (because of peripheral sensory neuropathy) and subsequently bevacizumab (because of back pain); one patient who discontinued bevacizumab because of cardiac failure accompanied by proteinuria but continued paclitaxel; and one who discontinued paclitaxel because of fatigue but continued bevacizumab.
Discussion
The efficacy of bevacizumab plus paclitaxel combination therapy in this subgroup analysis of Japanese patients treated in the MERiDiAN trial is consistent with that observed in the ITT population of MERiDiAN (4) (Supplementary Table 2 ) and similar to the previously reported single-arm Japanese JO19901 study evaluating first-line bevacizumab plus paclitaxel in 120 Japanese patients with HER2-negative mBC (5) . Median PFS with bevacizumab-paclitaxel was 12.7 months (95% CI, 10.9 months-not evaluable) in the present subgroup analysis compared with 11.0 months (95% CI, 9.5-12.2 months) in the ITT population of MERiDiAN (4). In the JO19901 study, median PFS was 12.9 months (95% CI, 11.1-18.2 months) according to IRF assessment and 14.9 months (95% CI, 11.1-18.2 months) according to investigator assessment (5). In MERiDiAN, the point estimate for the PFS HR in the Japanese subgroup (0.64) was very similar to that in the ITT population (0.68), although not surprisingly in such a small subgroup, the 95% CIs were wide and crossed 1.
In the MERiDiAN trial, the response rate to bevacizumabpaclitaxel was 58% in Japanese patients and 54% in the ITT population, compared with 74% in JO19901 (5) . Although the response rate seems slightly lower in MERiDiAN, the disease control rates were very similar (92% versus 95% in JO19901). The 4% rate of primary resistance (disease progression as best response) in MERiDiAN is remarkably low. Interim OS results in the Japanese subgroup were consistent with those in the MERiDiAN ITT population. Final OS analysis is anticipated in 2017.
The safety profile of bevacizumab-paclitaxel in Japanese patients treated in MERiDiAN was generally consistent with that observed in the JO19901 study. The incidence of neutropenia and associated complications in this subgroup analysis differed slightly from that observed in JO19901, but the comparison is difficult to interpret because JO19901 used version 3.0 of CTCAE and the MERiDiAN trial used version 4.0. Reassuringly, there were no cases of Grade ≥3 wound-healing complications, gastrointestinal perforation, thromboembolic events or bleeding among Japanese patients treated in the MERiDiAN trial. The incidence of Grade ≥3 hypertension in the Japanese subgroup of the MERiDiAN trial was similar to that in the JO19901 study (13% versus 17%, respectively), although again limited by the difference in grading of hypertension (version 4.0 being more stringent than version 3.0).
For several adverse events, the incidence in the Japanese subgroup reported here was substantially higher than in the ITT population reported by Miles et al. (4) . For example, alopecia (all grades) was reported in 90% and 96% of patients treated with placebo-paclitaxel versus bevacizumab-paclitaxel, respectively, in the Japanese subgroup, compared with 61% versus 57%, respectively, in the ITT population. Similarly, peripheral sensory neuropathy was reported in 76% and 83%, respectively, in the Japanese subgroup compared with 36% and 38%, respectively, in the ITT population. As the incidences were increased in both the bevacizumab arm and the non-bevacizumab arm, the most likely explanations seem to be more intense reporting of adverse events in Japanese centers, cultural differences in the perception of adverse events or differences in the tolerability of paclitaxel in Japanese populations compared with the rest of the world. The literature includes several reports of increased toxicity in Asian patients receiving paclitaxel or other anticancer agents (6) (7) (8) (9) (10) . In a meta-analysis of more than 4000 patients treated for non-small-cell lung cancer in bevacizumab trials, the rate of Grade ≥3 proteinuria was significantly higher in Asian than non-Asian patients, whereas the rates of severe bleeding and thromboembolism were significantly lower (10) . However, in the present analysis of patients with breast cancer, there were no cases of Grade ≥3 proteinuria, nor of Grade ≥3 thromboembolism or bleeding. Overall, our findings are consistent with a recently published report of Japanese patients treated with bevacizumab for colorectal cancer (11) , showing no new safety signals compared with previous reports of bevacizumab therapy in global populations. Interestingly, the mean dose intensity of paclitaxel was lower in the bevacizumab-paclitaxel arm (75.9%) than the placebo-paclitaxel arm (89.5%). This appears to be driven by the higher proportion of patients requiring paclitaxel dose modifications. However, with dose modification, patients in the bevacizumab-paclitaxel arm were able to continue therapy for prolonged periods, as indicated by the longer median duration of paclitaxel in the bevacizumab-paclitaxel arm compared with the placebo-paclitaxel arm (8.8 vs 7.6 months, respectively). Furthermore, the efficacy results suggest that the lower paclitaxel dose intensity has not compromised efficacy and instead enabled long-term treatment with paclitaxel.
The small numbers of patients in the present exploratory subgroup analyses preclude any insight into efficacy according to baseline plasma VEGF-A level. The 95% CI for the PFS HR in patients with high baseline VEGF-A levels is wide and overlaps broadly with the 95% CI for the PFS HR in the overall population. Of note, the treatment-by-VEGF-A interaction test in the ITT population, which was a prespecified secondary endpoint, did not support using baseline plasma VEGF-A as a predictive biomarker for treatment benefit from bevacizumab (4). In the Japanese subgroup, the proportion of patients with high plasma VEGF-A was substantially lower in the bevacizumab arm than the chemotherapy-alone arm. As high plasma VEGF-A level is associated with a worse prognosis (but importantly, does not predict increased PFS benefit from bevacizumab), this imbalance should be taken into consideration when interpreting the median PFS estimate.
The main limitations of our findings are the exploratory nature of the analyses and the small sample size. Geographic region was a stratification factor in MERiDiAN, with one of the strata being 'Asian'. However, the Asian subgroup in the parent study included 92 patients, and thus the present analyses in 54 Japanese patients include only a subset of this stratum. PFS results in the Asian subgroup showed an HR of 0.75 (95% CI, 0.42-1.31) and median PFS of 9.2 months with placebo-paclitaxel versus 11.3 months with bevacizumab-paclitaxel.
Slight imbalances in baseline characteristics were observed between the two treatment arms of the Japanese subgroup with respect to triple-negative disease status and prior taxane therapy. These imbalances may contribute to the slightly longer median PFS in the Japanese subgroup treated with bevacizumab-paclitaxel. However, in the placebo-paclitaxel arm, median PFS was also longer in the Japanese subgroup than in the ITT population despite the higher frequency of these characteristics typically associated with worse PFS. This observation suggests that other factors may contribute to the slightly more favorable PFS outcomes in the Japanese subgroup.
In summary, median PFS of 12.7 months in the present subgroup analysis is within the range reported for the bevacizumab plus paclitaxel combination in randomized Phase III trials (1, 4, 12, 13) and the single-arm JO19901 study in Japanese patients (5), notwithstanding the caveats described above. Our analyses provide further support for the use of first-line bevacizumab-paclitaxel treatment for Japanese patients with HER2-negative LR/mBC.
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